Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Contrafect (CFRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,903
  • Shares Outstanding, K 79,410
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,680 K
  • 60-Month Beta -0.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.20
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.13
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/09/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.43 +5.35%
on 05/20/19
0.61 -25.74%
on 05/03/19
-0.08 (-14.62%)
since 04/18/19
3-Month
0.36 +25.83%
on 03/19/19
0.80 -43.38%
on 04/10/19
-0.01 (-1.52%)
since 02/20/19
52-Week
0.35 +27.61%
on 02/07/19
2.93 -84.54%
on 07/12/18
-1.36 (-74.97%)
since 05/18/18

Most Recent Stories

More News
ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, comprised of lysins and amurins, a new modality in therapeutics...

CFRX : 0.45 (-7.53%)
ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today...

CFRX : 0.45 (-7.53%)
Detailed Research: Economic Perspectives on America First Multifamily Investors, Pluralsight, Globus Medical, ContraFect, Moleculin Biotech, and RumbleON -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of America First Multifamily Investors,...

PS : 33.29 (-1.60%)
RMBL : 4.95 (+0.20%)
ATAX : 7.11 (+0.14%)
GMED : 41.67 (-2.18%)
CFRX : 0.45 (-7.53%)
MBRX : 1.13 (-2.59%)
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies...

MLNT : 2.98 (-2.93%)
ETTX : 6.45 (-2.88%)
ITRM : 7.03 (-0.71%)
CFRX : 0.45 (-7.53%)
MTFB : 1.86 (-1.59%)
SMMT : 1.71 (+6.21%)
SCYX : 1.40 (-2.78%)
CDTX : 1.97 (-2.48%)
NBRV : 2.39 (-7.36%)
PRTK : 4.24 (-6.81%)
ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today...

CFRX : 0.45 (-7.53%)
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today...

CFRX : 0.45 (-7.53%)
ContraFect Announces CEO Transition

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapies for life-threatening, drug-resistant infectious...

CFRX : 0.45 (-7.53%)
ContraFect to Present at the Bacteriophage Therapy Summit

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant...

CFRX : 0.45 (-7.53%)
ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant...

CFRX : 0.45 (-7.53%)
ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.45 (-7.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CFRX with:

Business Summary

ContraFect Corporation is a biotechnology company. The Company is focused on protein and antibody therapeutic products for life-threatening infectious diseases. Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment...

See More

Key Turning Points

2nd Resistance Point 0.54
1st Resistance Point 0.50
Last Price 0.45
1st Support Level 0.42
2nd Support Level 0.39

See More

52-Week High 2.93
Fibonacci 61.8% 1.95
Fibonacci 50% 1.64
Fibonacci 38.2% 1.34
Last Price 0.45
52-Week Low 0.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar